AYUSH Medical Education & CME Platform Ayurveda

Evaluation of hepatoprotective and hypolipidemic effects of kutaki

Introduction Botanical and Ayurvedic overview: Kutaki (Picrorhiza kurroa Royle ex Benth.), a medicinal herb belonging to the Scrophulariaceae family, is widely described in classical Ayurvedic literature, including Charaka Samhita, Sushruta Samhita, Ashtanga Samgraha, and Dhanvantari Nighantu. It is known by several synonyms such as Matsyashakala, Katuka, Tikta, Chakrangi, Ashokarohini, Tiktarohini, Katurohini, Arishta, and Janani. According to Ayurveda, Kutaki possesses Katu and Tikta rasa, Laghu guna, Ushna virya, and Katu vipaka. It exhibits Deepana, Bhedana, Kaphapittahara, Jvarahara, and Yakritottejaka properties. Acharya Charaka classified it under Lekhaniya, Bhedaniya, and Stanyashodhana Mahakashaya, whereas Acharya Sushruta included it in Mustadi, Pippalyadi, and Patoladi gana. Kutaki is also a key ingredient in several classical formulations described in Sharangadhara Samhita. The name Picrorhiza is derived from the Greek words “picros” (bitter) and “rhiza” (root), referring to its intensely bitter rhizome. The plant is predominantly found in the Himalayan region, and its roots and rhizomes are the primary medicinal parts used. Phytochemical constituents The principal bioactive component of Kutaki is kutkin, a mixture of kutkoside and iridoid glycosides, including picrosides I, II, and III. Other important constituents include apocynin, drosin, cucurbitacin glycosides, flavonoids, triterpenes, alkaloids, coumarins, sterols, and tannins. These phytochemicals contribute to its hepatoprotective, antioxidant, anti-inflammatory, anticholestatic, and immunomodulatory activities. Pharmacological importance of Kutaki Kutaki is extensively used in the management of hepatic and metabolic disorders due to its hepatoprotective, hypolipidemic, antioxidant, and anti-inflammatory properties. Experimental and clinical studies have demonstrated its ability to protect hepatocytes against toxic insults, improve liver function, and regulate lipid metabolism. Evidence from preclinical and clinical studies Effects in nonalcoholic fatty liver disease: In a high-fat diet-induced nonalcoholic fatty liver disease (NAFLD) model, hydroalcoholic extract of Kutaki significantly reduced hepatic lipid accumulation and fatty infiltration.1 Histopathological findings demonstrated restoration of normal liver architecture, with the 400 mg/kg dose showing superior efficacy compared with silymarin. Hypolipidemic activity: Studies in hyperlipidemic animal models have shown that aqueous extracts of Kutaki significantly reduce serum lipid levels, liver weight, SGOT, and SGPT concentrations. Improvements in high-density lipoprotein (HDL) levels and reductions in body weight further support its role in metabolic disorders associated with dyslipidemia and fatty liver disease. Clinical studies in liver disorders: A double-blind, placebo-controlled clinical trial in patients with viral hepatitis demonstrated significant improvement in liver function parameters following treatment with Kutaki alone or as a component of Arogyavardhini Vati. Patients receiving Kutaki exhibited faster normalization of bilirubin levels compared with the placebo group. Further investigations on picrosides confirmed their antioxidant and hydrocholeretic activities, providing mechanistic support for the hepatoprotective effects observed in experimental and clinical studies. A standardized cucurbitacin-free extract, Picroliv, has also undergone clinical evaluation. Protection against drug-induced hepatotoxicity: Clinical studies have shown that Kutaki co-administered with atorvastatin prevented deterioration of liver function parameters compared with placebo, indicating a protective effect against drug-induced hepatotoxicity. Experimental studies have further demonstrated hepatoprotection against acetaminophen, carbon tetrachloride, galactosamine, ethanol, aflatoxin B1, thioacetamide, oxytetracycline, and monocrotaline-induced liver injury. Nephroprotective activity: Animal studies using cisplatin-induced nephrotoxicity models reported significant reductions in serum creatinine and blood urea levels following administration of Kutaki extracts and Arogyavardhini Vati. These findings suggest additional nephroprotective potential beyond its hepatic benefits. Mechanisms of action Antioxidant activity: Kutaki exerts potent antioxidant effects by scavenging reactive oxygen species and inhibiting lipid peroxidation.2 Picroside-I and kutkoside reduce the generation of superoxide anions and malondialdehyde while enhancing endogenous antioxidant defenses, including glutathione stores. Hepatoprotective activity: Kutaki protects hepatocytes by stabilizing cellular membranes, reducing oxidative stress, and enhancing liver regeneration. Experimental studies have shown normalization of serum transaminases, bilirubin, and lipid profiles following treatment with Kutaki extracts. Choleretic and anticholestatic effects: Picroliv and other active constituents promote bile secretion and improve biliary function. Comparative studies have demonstrated anticholestatic and choleretic activities comparable to or greater than those of silymarin. Hypolipidemic activity: Kutaki regulates lipid metabolism by reducing serum cholesterol, triglycerides, and hepatic lipid accumulation. Its lipid-lowering effects are attributed to bioactive compounds such as picrosides, cucurbitacins, flavonoids, and phytosterols. Anti-inflammatory activity: Apocynin, a major constituent of Kutaki, exhibits significant anti-inflammatory activity by reducing inflammatory mediators and oxidative stress, thereby contributing to hepatoprotection and metabolic regulation. Discussion From an Ayurvedic perspective, Kutaki possesses Deepana, Lekhana, Bhedana, Kaphapittahara, and Yakritottejaka properties, which support digestive function, lipid metabolism, detoxification, and liver health. Modern pharmacological studies corroborate these traditional claims by demonstrating hepatoprotective, antioxidant, hypolipidemic, anti-inflammatory, and regenerative effects. The cumulative evidence suggests that Kutaki may be beneficial in the management of NAFLD, viral hepatitis, dyslipidemia, drug-induced liver injury, and other hepatic disorders. Its ability to modulate oxidative stress, inflammation, and lipid metabolism makes it a promising therapeutic agent for metabolic liver diseases. Conclusion Kutaki (Picrorhiza kurroa) is a well-established Ayurvedic medicinal plant with significant hepatoprotective, hypolipidemic, antioxidant, anti-inflammatory, and nephroprotective properties. Preclinical and limited clinical evidence supports its potential role in managing NAFLD, viral hepatitis, dyslipidemia, and drug-induced liver injury. However, most available data are derived from animal studies. Well-designed human clinical trials are needed to further establish its efficacy, safety, and therapeutic mechanisms in liver and metabolic disorders.3 References: Shetty SN, Mengi S, Vaidya R, Vaidya AD. A study of standardized extracts of Picrorhiza kurroa Royle ex Benth in experimental nonalcoholic fatty liver disease. J Ayurveda Integr Med. 2010;1(3):203-210. doi:10.4103/0975-9476.72622. https://pmc.ncbi.nlm.nih.gov/articles/PMC3087357/ Hassan F, Khan AU, Zaidi SZUH, Niazi MK, Ismail MA. In Vitro Antioxidant and Inhibitory Study of Picrorhiza kurroa (Kutki), Syzygium aromaticum (Loung), Lawsonia inermis (Henna), Rheum emodi (Revand Chini), Curcuma longa (Haldi) Against Lipid Per-Oxidation in Mice Brain and Liver. Dose Response. 2023;21(4):15593258231210431. Published 2023 Oct 25. doi:10.1177/15593258231210431. https://pmc.ncbi.nlm.nih.gov/articles/PMC10605699/ Misar S. Hepatoprotective and hypolipidemic effect of Kutaki (Picrorhiza kurroa ROYLE ex Benth.)-A. IJRAR. February 2019, Volume 6, Issue 1. https://www.researchgate.net/publication/339079904_HEPATOPROTECTIVE_AND_HYPOLIPIDEMIC_EFFECT_OF_KUTAKI_PICRORHIZA_KURROA_ROYLE_EX_BENTH-A_REVIEW

Explore Content

Expert-Led Learning Clinically Relevant CME & Webinars

Evaluation of hepatoprotective and hypolipidemic effects of kutaki

AYUSH Medical Education & CME Platform Yoga & Naturopathy

Ayurvedic perspective on non-alcoholic fatty liver disease and its management

Introduction Ayurveda is one of the oldest holistic medical systems, originating in India over 5,000 years ago and emphasizing the maintenance of health through harmony between individual constitution and natural environment. It focuses on prevention and restoration of physiological balance through diet, lifestyle, and therapeutic interventions. In the modern era, rapid urbanization, sedentary behavior, and dietary excess have contributed to a marked rise in lifestyle disorders, including obesity, type 2 diabetes mellitus, dyslipidemia, and non-alcoholic fatty liver disease (NAFLD). These conditions are broadly comparable to Santarpanajanya Vyadhi in Ayurveda, primarily driven by Kapha and Meda Dhatu vitiation. NAFLD is a progressive metabolic liver disorder characterized by hepatic fat accumulation ranging from simple steatosis to steatohepatitis, fibrosis, cirrhosis, and hepatocellular carcinoma. Its increasing prevalence is strongly associated with obesity, insulin resistance, and metabolic syndrome, with limited definitive pharmacological treatment options. Ayurvedic perspective and etiopathogenesis Nidana (causative factors): Ayurveda describes NAFLD-related pathology under Beejadushti, Aharaja, Viharaja, and Manasika Nidana, corresponding to genetic, dietary, lifestyle, and psychological factors. Beejadushti (genetic factors): Genetic predisposition leads to structural and functional abnormalities of metabolic tissues, contributing to altered lipid handling and increased susceptibility to Meda accumulation, analogous to modern genetic polymorphisms influencing NAFLD progression. Aharaja hetu (dietary factors): Excess intake of Guru, Snigdha, Madhura, and Abhishyandi foods, along with incompatible diets, leads to Agnimandya and Ama formation. This promotes Meda Dhatu accumulation and hepatic lipid deposition. Viharaja hetu (lifestyle factors): Sedentary behavior, daytime sleep, and reduced physical activity impair metabolic efficiency and contribute to Kapha aggravation and weight gain. Manasika hetu (psychological factors): Stress, anxiety, anger, and disturbed sleep impair digestion and metabolism through Agni suppression, leading to systemic metabolic imbalance. Modern etiological correlates Genetic factors: NAFLD is associated with multiple gene variants affecting lipid metabolism, insulin resistance, oxidative stress, inflammation, and fibrosis (e.g., PNPLA3, TM6SF2, TLR4, TNF, IL6). Dietary and lifestyle factors: High-fat diets, refined carbohydrates, sedentary behavior, smoking, and alcohol-independent metabolic overload contribute to hepatic steatosis and insulin resistance. Metabolic syndrome and diabetes: NAFLD strongly correlates with metabolic syndrome, characterized by dyslipidemia, hypertension, hyperglycemia, and central obesity, with risk increasing as metabolic abnormalities accumulate. Associated clinical conditions: Polycystic ovarian syndrome (PCOS) and obstructive sleep apnea (OSA) further increase insulin resistance and systemic inflammation, accelerating NAFLD progression. Samprapti (pathogenesis): Nidana sevana → Agnimandya → Ama formation → Srotorodha → Meda Dhatu vitiation → abnormal lipid deposition in Yakrit → hepatic dysfunction (Yakritmeda) → clinical manifestations such as fatigue, indigestion, hepatomegaly, and metabolic imbalance. Clinical features NAFLD is often asymptomatic in early stages. Common features include fatigue, abdominal heaviness, malaise, hepatomegaly, and metabolic disturbances, with many patients being overweight or obese. Management approach Conventional management: Lifestyle modification remains the cornerstone of treatment, including weight reduction, dietary control, and physical activity. Pharmacotherapy is limited and includes agents such as insulin sensitizers and antioxidants with variable efficacy. Ayurvedic management: Nidana parivarjana: Avoidance of Kapha–Meda aggravating factors such as heavy, oily foods, sedentary behavior, daytime sleep, and incompatible diet forms the primary intervention. Shodhana chikitsa: Detoxification therapies are indicated in selected cases: Virechana for Pitta–Kapha elimination and hepatic cleansing Vamana for Kapha reduction and metabolic activation Raktamokshana in specific inflammatory conditions Shamana chikitsa: Herbs with Tikta, Kashaya rasa and Deepana–Pachana properties such as Guduchi, Katuki, Bhumi amalaki, Pippali, and Haritaki support hepatic metabolism and reduce fat accumulation. Rasayana chikitsa: Rejuvenative agents like Triphala, Guggulu, Shilajatu, and Bhallataka improve antioxidant status, tissue regeneration, and metabolic resilience. Yoga and physical activity: Regular exercise and yogic practices such as Surya Namaskara, Pranayama, and selected asanas improve insulin sensitivity, reduce weight, and normalize metabolic function. Lifestyle modification: Regular exercise, dietary discipline, fasting where appropriate, and avoidance of sedentary habits are essential for long-term disease control. Pathya and Apathya Pathya Ahara: Food group Pathya (wholesome diet) Apathya (unwholesome diet) Cereals Rice, wheat, oats, barley New rice, rice flour Pulses Green gram, red gram, lentils Sesame, chickpeas, kidney beans, black lentils Fruits Grapes (Draksha), custard apple, pomegranate, apple, kiwi, papaya Orange, lemon, mango, watermelon Vegetables Bottle gourd (Potala), drumstick (Shigru/Sahijan), beans, brinjal, potato, Jeevanti, Punarnava, radish, carrot, beetroot Chilli, bitter gourd, pickles, pumpkin, all leafy vegetables (Saka) Milk products Ghee, milk, cheese Curd, sweetened milk products, paneer Beverages Gomutra, Asava, Arishta Soda, cold drinks, salted water Conclusion NAFLD represents a multifactorial metabolic disorder with strong overlap with Ayurvedic Santarpanajanya Vyadhi. Integrative management combining dietary regulation, Panchakarma, herbal therapy, yoga, and lifestyle modification offers a comprehensive approach to disease prevention and progression control. However, further high-quality clinical studies are required to validate and standardize Ayurvedic interventions in NAFLD management.1 References: Panjeta N. NON-ALCOHOLIC FATTY LIVER DISEASE AND ITS MANAGEMENT- A CRITICAL REVIEW. wjpmr, 2025, 11(6), 4-11. https://www.wjpmr.com/download/article/135052025/1748685146.pdf

Explore Content

Expert-Led Learning Clinically Relevant CME & Webinars